NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Status Completed

Clinical Trial Summary

NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression with suicidal ideation. This study will test the hypothesis that NRX-101 is superior to lurasidone alone (standard of care) in maintaining remission from symptoms of depression (primary endpoint) and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.

Clinical Trial Description

Background and Rationale: NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NRX-101 is composed of D-cycloserine (DCS) an NMDA antagonist and lurasidone (5HT2a atypical antipsychotic and antidepressant). In a phase 2 clinical study of bipolar depression and acute suicidal ideation and behavior, (in patients requiring hospitalization) patients received an initial infusion of ketamine and then NRX-101 for 6 weeks. In that phase 2 study, NRX-101 showed the ability to maintain remission from depression and suicidality over 6 weeks when taken twice daily. In this current out patient study, patients with bipolar depression and subacute suicidality (not requiring hospitalization), ketamine will not be used. Primary Objective: - To test the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization. Secondary Objectives: • To test the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in reducing suicidality in depressed bipolar patients with SSIB, as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) Methodology: : A multi-center, randomized, double-blind, trial in which patients with bipolar depression (MADRS ≥30) and subacute levels of suicidal ideation (C-SSRS 3 or 4, not requiring hospitalization) are randomized to receive twice daily oral NRX-101 or lurasidone (standard of care). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03395392
Study type	Interventional
Source	NeuroRx, Inc.
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	May 12, 2022
Completion date	March 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03256162` - Ketamine as an Adjunctive Therapy for Major Depression	Phase 1
Recruiting	`NCT03396744` - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression	Phase 1/Phase 2
Completed	`NCT01914393` - Pediatric Open-Label Extension Study	Phase 3
Active, not recruiting	`NCT03641300` - Efficacy of Convulsive Therapies for Bipolar Depression	N/A
Completed	`NCT02363738` - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression	Phase 2
Terminated	`NCT01807741` - Asenapine for Bipolar Depression	Phase 2
Recruiting	`NCT01213121` - Neurophysiologic Changes in Patients With Bipolar Depression	Phase 4
Completed	`NCT01919892` - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium	Phase 4
Completed	`NCT00762268` - A Trial of SAMe for Treatment-Resistant Bipolar Depression	N/A
Terminated	`NCT00566111` - Ceftriaxone in the Management of Bipolar Depression	N/A
Terminated	`NCT00217217` - Low Field Magnetic Stimulation Treatment for Bipolar Depression	Phase 3
Recruiting	`NCT04998773` - Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression	N/A
Recruiting	`NCT04939649` - Ketamine as an Adjunctive Therapy for Major Depression (2)	Phase 3
Completed	`NCT03658824` - Behavioural Activation for Bipolar Depression: A Case Series	N/A
Suspended	`NCT03674671` - Ketamine Versus Electroconvulsive Therapy in Depression	Phase 3
Recruiting	`NCT05340686` - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression	N/A
Recruiting	`NCT05296356` - OSU6162 in Bipolar Depression (OBID)	Phase 2
Recruiting	`NCT03711019` - Efficacy of Convulsive Therapies During Continuation	N/A
Completed	`NCT02088580` - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients	N/A
Terminated	`NCT00272025` - Treatment Resistant Bipolar Depression	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.